China Sets Up Committee For Pharmaceutical Research Intellectual Property Rights
This article was originally published in PharmAsia News
Executive Summary
Chinese Pharmaceutical Association's Committee for Pharmaceutical Research Intellectual Property Rights, the first professional organization in the field, recently held its first plenary meeting in Beijing. The committee was set up with the objectives of bridging communication among authorities, societies, pharmaceutical enterprises and public institutions; providing advice on IP rights strategy for the nation, pharmaceutical industry and enterprises; and offering consultations for China's decision makers. Its role will be to promote the establishment of a scientific, rational and strict pharmaceutical IP rights system to support pharmaceutical innovation; provide advice for the industry and government by initiating research on TCM IP rights in international trading; and groom technical expertise in a planned and systematic way. (Click here for more - Chinese language)
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.